Clinical biomarkers in metabolic syndrome

Nutrition in Clinical Practice

Volumn 29, Issue 2, 2014, Pages 215-221

  Barazzoni, Rocco ^a   Silva, Veronica ^b   Singer, Pierre ^b,c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

biological markers; biomarkers; insulin resistance; metabolic syndrome X; nutrition therapy

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; I KAPPA B; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PALMITIC ACID; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; SATURATED FATTY ACID; SPHINGOLIPID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ABDOMINAL FAT; ABDOMINAL OBESITY; ADIPOSE TISSUE; BODY MASS; CALORIC INTAKE; CARBOHYDRATE INTAKE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DEATH; DEPRESSION; ENERGY BALANCE; FRAMINGHAM RISK SCORE; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; INSULIN RESPONSE; INTRAABDOMINAL FAT; LEISURE; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID DIET; LIPID STORAGE; LIVER; MACROPHAGE ACTIVATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITION; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PREVALENCE; PROGNOSIS; REVIEW; SEDENTARY LIFESTYLE; SKELETAL MUSCLE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

BIOLOGICAL MARKERS; BIOMARKERS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NUTRITION THERAPY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIET; HUMANS; METABOLIC SYNDROME X; NUTRITIONAL STATUS; OBESITY;

EID: 84896359972     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533613516168     Document Type: Review

References (106)

1. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012 ; 70 (1). 3-21
2. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 ; 120 (16). 1640-1645
3. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 ; 56 (14). 1113-1132
4. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care. 2004 ; 27 (11). 2676-2681
5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 ; 37 (12). 1595-1607
6. Valdez R, Seidell JC, Ahn YI, Weiss KM. A new index of abdominal adiposity as an indicator of risk for cardiovascular disease. A cross-population study. Int J Obes Relat Metab Disord. 1993 ; 17 (2). 77-82
7. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. Circulation. 2008 ; 117 (13). 1658-1667
8. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001 ; 108 (3). 437-446
9. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004 ; 114 (12). 1752-1761
10. Supinski GS, Callahan LA. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol. 2007 ; 102 (5). 2056-2063
11. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab. 2008 ; 294 (2). E345-351
12. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009 ; 119 (3). 573-581
13. Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci U S A. 2003 ; 100 (13). 7996-8001
14. Barazzoni R. Skeletal muscle mitochondrial protein metabolism and function in ageing and type 2 diabetes. Curr Opin Clin Nutr Metab Care. 2004 ; 7 (1). 97-102
15. Befroy DE, Petersen KF, Dufour S, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes. 2007 ; 56 (5). 1376-1381
16. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 ; 116 (7). 1793-1801
17. Romano M, Guagnano MT, Pacini G, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab. 2003 ; 88 (11). 5321-5326
18. Chen J, Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004 ; 27 (12). 2960-2965
19. Doumatey AP, Lashley KS, Huang H, et al. Relationships among obesity, inflammation, and insulin resistance in African Americans and West Africans. Obesity. 2010 ; 18 (3). 598-603
20. Urakawa H, Katsuki A, Sumida Y, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab. 2003 ; 88 (10). 4673-4676
21. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 2005 ; 28 (7). 1757-1762
22. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007 ; 2 (3). 550-562
23. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013 ; 36 (1). 145-149
24. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Pirulli A, Barazzoni R. Metabolic syndrome and chronic kidney disease. J Ren Nutr. 2010 ; 20: S19-23
25. Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med. 2007 ; 262 (4). 470-478
26. Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012 ; 35 (5). 1171-1180
27. Barazzoni R, Zanetti M, Ferreira C, et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab. 2007 ; 92 (10). 3935-3940
28. Barazzoni R, Zanetti M, Nagliati C, et al. Gastric bypass does not normalize obesity-related changes in ghrelin profile and leads to higher acylated ghrelin fraction. Obesity. 2013 ; 21 (4). 718-722
29. Bonnard C, Durand A, Peyrol S, et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J Clin Invest. 2008 ; 118 (2). 789-800
30. Valerio A, Cardile A, Cozzi V, et al. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest. 2006 ; 116 (10). 2791-2798
31. Kleemann R, van Erk M, Verschuren L, et al. Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PloS One. 2010 ; 5 (1). e8817
32. Rachek LI, Musiyenko SI, LeDoux SP, Wilson GL. Palmitate induced mitochondrial deoxyribonucleic acid damage and apoptosis in l6 rat skeletal muscle cells. Endocrinology. 2007 ; 148 (1). 293-299
33. Yuzefovych L, Wilson G, Rachek L. Different effects of oleate vs. palmitate on mitochondrial function, apoptosis, and insulin signaling in L6 skeletal muscle cells: role of oxidative stress. Am J Physiol Endocrinol Metab. 2010 ; 299 (6). E1096-1105
34. Barazzoni R, Zanetti M, Gortan Cappellari G, et al. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-kappaB inhibitor (IkappaB)-nuclear factor-kappaB (NFkappaB) activation in rat muscle, in the absence of mitochondrial dysfunction. Diabetologia. 2012 ; 55 (3). 773-782
35. Richardson DK, Kashyap S, Bajaj M, et al. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem. 2005 ; 280 (11). 10290-10297
36. Paolisso G, Gambardella A, Tagliamonte MR, et al. Does free fatty acid infusion impair insulin action also through an increase in oxidative stress?. J Clin Endocrinol Metab. 1996 ; 81 (12). 4244-4248
37. Storlien LH, Baur LA, Kriketos AD, et al. Dietary fats and insulin action. Diabetologia. 1996 ; 39 (6). 621-631
38. Jans A, Konings E, Goossens GH, et al. PUFAs acutely affect triacylglycerol-derived skeletal muscle fatty acid uptake and increase postprandial insulin sensitivity. Am J Clin Nutr. 2012 ; 95 (4). 825-836
39. Warensjo E, Riserus U, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia. 2005 ; 48 (10). 1999-2005
40. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010 ; 375 (9733). 2267-2277
41. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest. 2011 ; 121 (11). 4222-4230
42. Othman A, Rutti MF, Ernst D, et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?. Diabetologia. 2012 ; 55 (2). 421-431
43. Brozinick JT, Hawkins E, Hoang Bui H, et al. Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int J Obes (Lond). 2013 ; 37 (8). 1064-1070
44. Finley CE, Barlow CE, Halton TL, Haskell WL. Glycemic index, glycemic load, and prevalence of the metabolic syndrome in the cooper center longitudinal study. J Am Diet Assoc. 2010 ; 110 (12). 1820-1829
45. Silva FM, Steemburgo T, de Mello VD, Tonding SF, Gross JL, Azevedo MJ. High dietary glycemic index and low fiber content are associated with metabolic syndrome in patients with type 2 diabetes. J Am Coll Nutr. 2011 ; 30 (2). 141-148
46. Kim K, Yun SH, Choi BY, Kim MK. Cross-sectional relationship between dietary carbohydrate, glycaemic index, glycaemic load and risk of the metabolic syndrome in a Korean population. Br J Nutr. 2008 ; 100 (3). 576-584
47. Liu AG, Most MM, Brashear MM, Johnson WD, Cefalu WT, Greenway FL. Reducing the glycemic index or carbohydrate content of mixed meals reduces postprandial glycemia and insulinemia over the entire day but does not affect satiety. Diabetes Care. 2012 ; 35 (8). 1633-1637
48. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J Nutr. 2009 ; 139 (6). 1263S - 1268S
49. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010 ; 90 (1). 23-46
50. Stanhope KL, Schwarz JM, Havel PJ. Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol. 2013 ; 24 (3). 198-206
51. Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care. 2010 ; 33 (11). 2477-2483
52. Stanhope KL, Havel PJ. Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am J Clin Nutr. 2008 ; 88 (6). 1733S - 1737S
53. Wennberg P, Gustafsson PE, Dunstan DW, Wennberg M, Hammarstrom A. Television viewing and low leisure-time physical activity in adolescence independently predict the metabolic syndrome in mid-adulthood. Diabetes Care. 2013 ; 36 (7). 2090-2097
54. Holme I, Tonstad S, Sogaard AJ, Larsen PG, Haheim LL. Leisure time physical activity in middle age predicts the metabolic syndrome in old age: results of a 28-year follow-up of men in the Oslo study. BMC Public Health. 2007 ; 7: 154
55. Workalemahu T, Gelaye B, Berhane Y, Williams MA. Physical activity and metabolic syndrome among Ethiopian adults. Am J Hypertens. 2013 ; 26 (4). 535-540
56. Lin YC, Chen JD, Chen PC. Excessive 5-year weight gain predicts metabolic syndrome development in healthy middle-aged adults. World J Diabetes. 2011 ; 2 (1). 8-15
57. Muzumdar R, Allison DB, Huffman DM, et al. Visceral adipose tissue modulates mammalian longevity. Aging Cell. 2008 ; 7 (3). 438-440
58. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004 ; 350 (25). 2549-2557
59. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005 ; 28 (12). 2926-2932
60. Fung GJ, Steffen LM, Zhou X, et al. Vitamin D intake is inversely related to risk of developing metabolic syndrome in African American and white men and women over 20 y: the Coronary Artery Risk Development in Young Adults study. Am J Clin Nutr. 2012 ; 96 (1). 24-29
61. Gagnon C, Lu ZX, Magliano DJ, et al. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab. 2012 ; 97 (6). 1953-1961
62. Mutt SJ, Karhu T, Lehtonen S, et al. Inhibition of cytokine secretion from adipocytes by 1,25-dihydroxyvitamin D(3) via the NF-kappaB pathway. FASEB J. 2012 ; 26 (11). 4400-4407
63. Chang E, Donkin SS, Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol. 2009 ; 307 (1-2). 77-82
64. Querfeld U, Hoffmann MM, Klaus G, et al. Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J Am Soc Nephrol. 1999 ; 10 (10). 2158-2164
65. Kayaniyil S, Vieth R, Harris SB, et al. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab. 2011 ; 96 (1). 168-175
66. Bo S, Rosato R, Ciccone G, et al. What predicts the occurrence of the metabolic syndrome in a population-based cohort of adult healthy subjects?. Diabetes Metab Res Rev. 2009 ; 25 (1). 76-82
67. Onat A, Ozhan H, Erbilen E, et al. Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. Int J Cardiol. 2009 ; 135 (2). 211-217
68. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care. 2005 ; 28 (3). 690-693
69. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005 ; 96 (5). 655-658
70. Goldstein BJ, Mahadev K, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes. 2005 ; 54 (2). 311-321
71. Rao VS, Nagaraj RK, Hebbagodi S, Kadarinarasimhiah NB, Kakkar VV. Association of inflammatory and oxidative stress markers with metabolic syndrome in Asian Indians in India. Cardiol Res Pract. 2010 ; 2011: 295976
72. Chen SJ, Yen CH, Huang YC, Lee BJ, Hsia S, Lin PT. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PloS One. 2012 ; 7 (9). e45693
73. Breen DM, Giacca A. Effects of insulin on the vasculature. Curr Vasc Pharmacol. 2011 ; 9 (3). 321-332
74. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care. 1991 ; 14 (3). 195-202
75. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. New Eng J Med. 1989 ; 320 (11). 702-706
76. Zavaroni I, Ardigo D, Rossi PC, et al. Relationship between plasma nitric oxide concentration and insulin resistance in essential hypertension. Am J Hypertens. 2004 ; 17 (7). 549-552
77. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007 ; 104 (31). 12587-12594
78. Monzillo LU, Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev. 2003 ; 61 (12). 397-412
79. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 ; 237 (3). E214-223
80. Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes Relat Metab Disord. 1999 ; 23 (5). 512-517
81. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 ; 28 (7). 412-419
82. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000 ; 23 (1). 57-63
83. Sung KC, Seo MH, Rhee EJ, Wilson AM. Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol. 2011 ; 10: 108
84. Andre P, Balkau B, Vol S, Charles MA, Eschwege E, Group DS. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care. 2007 ; 30 (9). 2355-2361
85. Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 ; 48 (6). 1253-1262
86. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol. 2010 ; 323 (1). 20-34
87. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002 ; 8 (11). 1288-1295
88. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006 ; 116 (7). 1784-1792
89. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995 ; 95 (5). 2111-2119
90. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003 ; 52 (7). 1779-1785
91. Barazzoni R, Bernardi A, Biasia F, et al. Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease - impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol. 2007 ; 293 (1). R47-54
92. Murano I, Barbatelli G, Parisani V, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res. 2008 ; 49 (7). 1562-1568
93. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 ; 112 (12). 1796-1808
94. Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A, Smith U. Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol Endocrinol Metab. 2009 ; 297 (5). E999 - E1003
95. Giordano A, Murano I, Mondini E, et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res. 2013 ; 54 (9). 2423-2436
96. Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. Am J Physiol Endocrinol Metab. 2009 ; 297 (5). E977-986
97. Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovasc Diabetol. 2011 ; 10 (1). 8
98. Kim JY, Ahn SV, Yoon JH, et al. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study. Diabetes Care. 2013 ; 36 (6). 1547-1553
99. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991 ; 266 (21). 3008-3011
100. Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998 ; 47 (8). 929-933
101. Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circulation. 2005 ; 69 (8). 928-933
102. Cirillo P, Sato W, Reungjui S, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol. 2006 ; 17: S165-168
103. Hara S, Tsuji H, Ohmoto Y, et al. High serum uric acid level and low urine pH as predictors of metabolic syndrome: a retrospective cohort study in a Japanese urban population. Metabolism. 2012 ; 61 (2). 281-288
104. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011 ; 60 (4). 1258-1269
105. Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, Johnson RJ, Lillo JL. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond). 2010 ; 34 (3). 454-461
106. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PloS One. 2012 ; 7 (10). e47948